AmerisourceBergen: Improving Therapy Initiation with AI

AmerisourceBergen: Improving Therapy Initiation with AI

This case study examines a real-world illustration of AI’s impact on therapy initiation for a leading biologic therapy manufacturer’s patients.

AI-Guided Patient Support Programs

A leading biologic therapy manufacturer, in collaboration with Lash Group and AllazoHealth, transformed therapy initiation through innovative AI-driven patient support.

The Challenge

Low First Fill Rates

The manufacturer of a leading biologic therapy was seeking a way to improve therapy initiation among targeted patient groups. Especially those who are at higher risk of not starting therapy.

The Solution

AI-Guided Patient Support Program

Predictive analytics flag the patients most likely to not initiate prescribed treatment and trigger AI-powered personalized interventions by channel, message, and timing. The manufacturer’s hub service partner, Lash Group, then executes appropriate interventions and the AllazoHealth AI platform digests the data from these follow-up actions. The platform continuously evolves as more patient data is aggregated and acted upon.

The Results

Accelerating First Fill Rates With Better Efficiency

The AI-driven adherence program supported the manufacturer’s objectives by accelerating first-fill rates while improving overall program efficiency. Including: an 8% increase in treatment initiation within 90 days of enrollment among patients with higher adherence risk and a 25% reduction in specific nurse call interventions due to AI targeting, enabling reallocation of nurse time to other needed interventions.

Download this free case study for a deeper understanding of how innovative patient support programs transform therapy initiation and improve patient outcomes. Fill out the form to get immediate access.

Fill out the form to download the case study